PYC Therapeutics (Australia) Buy Hold or Sell Recommendation
| PYC Stock | 1.40 0.05 3.45% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding PYC Therapeutics is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell PYC Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for PYC Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out PYC Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as PYC and provide practical buy, sell, or hold advice based on investors' constraints. PYC Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
PYC |
Execute PYC Therapeutics Buy or Sell Advice
The PYC recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on PYC Therapeutics. Macroaxis does not own or have any residual interests in PYC Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute PYC Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
PYC Therapeutics Trading Alerts and Improvement Suggestions
| PYC Therapeutics generated a negative expected return over the last 90 days | |
| PYC Therapeutics may become a speculative penny stock | |
| PYC Therapeutics has high historical volatility and very poor performance | |
| PYC Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 22.06 M. Net Loss for the year was (37.73 M) with profit before overhead, payroll, taxes, and interest of 15.81 M. | |
| PYC Therapeutics has accumulated about 15.57 M in cash with (38.59 M) of positive cash flow from operations. | |
| Roughly 59.0% of the company outstanding shares are owned by corporate insiders |
PYC Therapeutics Returns Distribution Density
The distribution of PYC Therapeutics' historical returns is an attempt to chart the uncertainty of PYC Therapeutics' future price movements. The chart of the probability distribution of PYC Therapeutics daily returns describes the distribution of returns around its average expected value. We use PYC Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of PYC Therapeutics returns is essential to provide solid investment advice for PYC Therapeutics.
| Mean Return | -0.01 | Value At Risk | -7.69 | Potential Upside | 5.71 | Standard Deviation | 4.31 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of PYC Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
PYC Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Capital Expenditures | 106.1K | 591.0K | 386.9K | 491.1K | 307.0K | 224.6K | |
| End Period Cash Flow | 7.2M | 18.4M | 29.1M | 15.6M | 66.9M | 70.2M | |
| Change In Cash | 1.1M | 11.2M | 10.7M | (13.5M) | 51.3M | 53.9M | |
| Free Cash Flow | (5.9M) | (12.4M) | (22.2M) | (24.9M) | (38.9M) | (37.0M) | |
| Depreciation | 547.1K | 622.4K | 839.5K | 882.0K | 1.1M | 1.1M | |
| Other Non Cash Items | 1.6M | 1.6M | 11.5M | 3.0M | 229.1K | 217.6K | |
| Net Income | (6.8M) | (17.8M) | (13.9M) | (22.8M) | (37.7M) | (35.8M) | |
| Change To Netincome | 472.0K | 2.8M | 182.2K | (554.2K) | (637.4K) | (605.5K) | |
| Change To Inventory | 1.0 | (2.7M) | (892.8K) | (4.2M) | (3.8M) | (3.6M) | |
| Investments | (13.7M) | (14.9M) | 33.1M | (477.1K) | (307.0K) | (322.4K) |
PYC Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to PYC Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that PYC Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a PYC stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.02 | |
β | Beta against Dow Jones | -0.18 | |
σ | Overall volatility | 3.84 | |
Ir | Information ratio | -0.01 |
PYC Therapeutics Volatility Alert
PYC Therapeutics exhibits very low volatility with skewness of 0.6 and kurtosis of 2.59. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure PYC Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact PYC Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.PYC Therapeutics Fundamentals Vs Peers
Comparing PYC Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze PYC Therapeutics' direct or indirect competition across all of the common fundamentals between PYC Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as PYC Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of PYC Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing PYC Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare PYC Therapeutics to competition |
| Fundamentals | PYC Therapeutics | Peer Average |
| Return On Equity | -0.7 | -0.31 |
| Return On Asset | -0.38 | -0.14 |
| Profit Margin | (1.71) % | (1.27) % |
| Operating Margin | (1.78) % | (5.51) % |
| Current Valuation | 587.49 M | 16.62 B |
| Shares Outstanding | 466.61 M | 571.82 M |
| Shares Owned By Insiders | 59.23 % | 10.09 % |
| Shares Owned By Institutions | 0.57 % | 39.21 % |
| Price To Book | 8.12 X | 9.51 X |
| Price To Sales | 29.61 X | 11.42 X |
| Revenue | 22.06 M | 9.43 B |
| Gross Profit | 15.81 M | 27.38 B |
| EBITDA | (38.12 M) | 3.9 B |
| Net Income | (37.73 M) | 570.98 M |
| Cash And Equivalents | 15.57 M | 2.7 B |
| Total Debt | 1.11 M | 5.32 B |
| Book Value Per Share | 0.02 X | 1.93 K |
| Cash Flow From Operations | (38.59 M) | 971.22 M |
| Earnings Per Share | (0.10) X | 3.12 X |
| Target Price | 8.75 | |
| Beta | 0.6 | -0.15 |
| Market Capitalization | 653.25 M | 19.03 B |
| Total Asset | 91.24 M | 29.47 B |
| Retained Earnings | (155.89 M) | 9.33 B |
| Working Capital | 76.51 M | 1.48 B |
| Net Asset | 91.24 M |
PYC Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as PYC . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 22808.33 | |||
| Daily Balance Of Power | (0.71) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 1.44 | |||
| Day Typical Price | 1.42 | |||
| Price Action Indicator | (0.06) | |||
| Period Momentum Indicator | (0.05) |
About PYC Therapeutics Buy or Sell Advice
When is the right time to buy or sell PYC Therapeutics? Buying financial instruments such as PYC Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having PYC Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Sovereign ETFs Thematic Idea Now
Broad Sovereign ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Sovereign ETFs theme has 14 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Sovereign ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for PYC Stock Analysis
When running PYC Therapeutics' price analysis, check to measure PYC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PYC Therapeutics is operating at the current time. Most of PYC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PYC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PYC Therapeutics' price. Additionally, you may evaluate how the addition of PYC Therapeutics to your portfolios can decrease your overall portfolio volatility.